.jpeg)
2026-10-21 02:51:20
On 19 Oct 2026 FDA acceleratedly approved Jemperli monotherapy for previously untreated adult stage II/III dMMR/MSI-H locally advanced rectal cancer; some patients may avoid chemoradiation and surgery. Based on single-arm phase II AZUR-1, durable benefit still needs long-term follow-up.
2026-10-21 02:43:10
Ibrutinib is used in adults with previously treated mantle cell lymphoma by blocking BTK signaling, but it does not guarantee cure. Monitor bleeding, infection, cytopenias, arrhythmia, and drug interactions; after progression consider non-covalent BTK inhibitors or CAR-T.
2026-10-20 07:32:48
Filgotinib is a selective JAK1 inhibitor for adults with moderate-to-severe RA after inadequate DMARD response and UC after conventional/biologic failure. RA is usually 200mg daily, 100mg in higher-risk patients; UC uses induction and maintenance phases. Watch serious infection, TB reactivation, herpes zoster, VTE, MACE, malignancy; pregnancy and lactation contraindicated.
2026-10-20 07:28:50
Daprodustat is for adults on dialysis at least 4 months with CKD anemia; it stimulates endogenous erythropoietin via HIF-PH inhibition. Not for non-dialysis patients, uncontrolled hypertension, or iron replacement. Watch MACE, VTE, access thrombosis, GI bleeding, and blood pressure.
2026-10-19 06:48:00
Pemigatinib is for previously treated unresectable or metastatic cholangiocarcinoma adults with confirmed FGFR2 fusion or rearrangement, not all biliary tract cancers. It blocks FGFR kinase signaling; monitor hyperphosphatemia, mucosal/skin reactions, and retinal pigment epithelial detachment symptoms.
2026-10-19 06:19:48
Cabozantinib can cause severe or fatal hemorrhage, while aspirin irreversibly inhibits platelet aggregation. Concomitant use raises the risk of GI bleeding, epistaxis, hematuria, and intracranial bleeding. Aspirin for coronary stent or stroke prevention should not be stopped by the patient; recent hemoptysis, active ulcer bleeding, or combined anticoagulation needs physician review.
2026-10-16 03:29:23
Bosentan is a dual endothelin receptor antagonist mainly used for pulmonary arterial hypertension, with emphasis on titration, liver monitoring, pregnancy contraindication, and drug interactions.
2026-10-16 03:26:11
Ambrisentan is mainly approved for pulmonary arterial hypertension, not as standard therapy for IgA nephropathy. Endothelin pathway research does not prove that ambrisentan safely reduces proteinuria in IgA nephropathy.
2026-10-14 04:43:35
Stiripentol is an oral antiseizure drug for Dravet-syndrome–related seizures in patients aged 6 months or older, weighing at least 7kg, and already receiving clobazam. It is not monotherapy. Use 50mg/kg/day in 2–3 divided doses, max 3000mg/day, with meals; monitor somnolence, appetite/weight loss, ataxia, neutropenia, thrombocytopenia, and clobazam interactions.
2026-10-14 04:40:08
This article reviews the mechanism, indications, dosing, toxicity management, and global clinical data of Selinexor, providing an objective reference for RRMM patients.
2026-10-13 07:01:50
Acalabrutinib is a selective BTK inhibitor that covalently blocks the BTK active-site cysteine and interrupts BCR downstream signaling in CLL/SLL and related B-cell tumors. It affects malignant and normal B cells, so infection, bleeding, arrhythmia, cytopenias, and resistance pathways all require structured monitoring.
2026-10-13 06:58:10
Bosutinib is an oral BCR-ABL and SRC-family tyrosine kinase inhibitor for newly diagnosed or resistant/intolerant Philadelphia chromosome-positive chronic-phase CML in adults, resistant/intolerant accelerated or blast-phase CML in adults, and chronic-phase CML in children aged 1 year and older. Main safety work covers diarrhea, liver injury, myelosuppression, and fluid retention.
